SCHEMBL6949237

SCHEMBL6949237

Cc1nc(NCCCN2CCCC2=O)c([N+](=O)[O-])c(N2CCc3ccccc3CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.46
PGK1 P00558 1/20 0.42
ALDH1A1 P00352 5/20 0.42
HPGD P15428 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 2/20 0.42
LMNA P02545 1/20 0.42
MALT1 Q9UDY8 1/20 0.42
RXFP1 Q9HBX9 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.40
CYP1A2 P05177 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6945708 0.85 GRIN2D (0.39) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL6947657 0.85 GRIN2D (0.39) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL6949324 0.84 KDM4E (0.52) ALDH1A1KDM4EHSD17B10LMNAHTT
SCHEMBL6949344 0.82 ALDH1A1 (0.52) ALDH1A1HPGDKDM4EHSD17B10LMNA
SCHEMBL6947517 0.73 MEN1 (0.44) ALDH1A1MEN1KMT2AHTTSMN1; SMN2
SCHEMBL6949469 0.71 POLB (0.43) MEN1KMT2AHTTSMN1; SMN2NPC1
SCHEMBL6951809 0.69 MEN1 (0.40) MEN1KMT2AHTTSMN1; SMN2NPC1
SCHEMBL6957503 0.69 MGMT (0.44) ALDH1A1MEN1KMT2AHTTSMN1; SMN2
SCHEMBL6953559 0.69 MAPT (0.49) KDM4EMEN1KMT2AHTTSMN1; SMN2
SCHEMBL6952315 0.68 MAPT (0.42) ALDH1A1LMNAMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed